Therapeutic potential of an anti-CCR9 mAb evidenced in xenografts of human CCR9+ tumors

Relapsed or refractory T acute lymphoblastic leukemia (T-ALL) still carries poor prognosis. Aiming to improve outcomes, the therapeutic potential of an anti-CCR9 monoclonal antibody (mAb 92R), targeting the human chemokine-receptor CCR9 is analyzed on orthotopic xenotransplants. 92R mAb treatment of mice carrying human CCR9(+) T-ALL cell lines or primary T cell leukemias inhibits tumor growth and increases survival. The therapeutic effects of 92R are specific and synergize with chemotherapeutic agents increasing survival. Furthermore, 92R decreases size of non-hematopoietic tumors with a forced CCR9 expression and of solid tumors generated by the pancreatic adenocarcinoma cell line AsPC-1. In addition, a humanized version of 92R mAb (Srb1) is also able to inhibit growth of CCR9(+) T-ALL tumor cells in vivo, increasing survival 2.66-fold. Finally, 92R mAb prevents liver accumulation of infiltrates and reduces tumor cell numbers in already formed infiltrates. Thus, the humanized version of 92R mAb (Srb1), displays therapeutic potential for CCR9(+) tumor treatment and might represent one of the first therapeutic antibodies for precision medicine on T-ALL patients.

Automated summary

Relapsed or refractory T-acute lymphoblastic leukemia (T-ALL) has a poor prognosis. An anti-CCR9 monoclonal antibody (mAb 92R) has been found to inhibit tumor growth and increase survival in T-ALL, and in combination with chemotherapy, it shows even better therapeutic effects. Furthermore, a humanized version of the antibody (Srb1) also has the potential to inhibit tumor growth.